NCT06710925View on ClinicalTrials.gov

A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

TNM001

single dose intramuscular injection

BIOLOGICAL

placebo

single dose intramuscular injection

Trial Locations (2)

404100

Children's Hospital of Chongqing Medical University, Chongqing

610000

West China Second University Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Zhuhai Trinomab Pharmaceutical Co., Ltd.

INDUSTRY